Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma

International Journal of Oncology

Volumn 37, Issue 3, 2010, Pages 605-614

  Nakamura, Keiichiro ^a   Abarzua, Fernando ^b   Hongo, Atsushi ^a   Kodama, Junichi ^a   Nasu, Yasutomo ^b   Kumon, Hiromi ^b   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b School of Medicine   (Japan)

Author keywords

HAI 1; HAI 2; Tumor suppressor gene; Uterine leiomyosarcoma

Indexed keywords

HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 2; SCATTER FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER PATIENT; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEIOMYOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE; TUMOR SUPPRESSOR GENE; UTERUS SARCOMA;

CELL AGGREGATION; CELL GROWTH PROCESSES; CELL MOVEMENT; CELL SURVIVAL; DISEASE-FREE SURVIVAL; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MEMBRANE GLYCOPROTEINS; PROGNOSIS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 77956519685     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000709     Document Type: Article

References (46)

1. Harlow BL, Weiss NS and Lofton S: The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 76: 399-402, 1986.
2. Arrastia CD, Fruchter RG, Clark M, Maiman M, Remy JC, Macasaet M, Gates EJ, Di Maio T and Marzec T: Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 65: 158-163, 1997.
3. Pautier P, Genestie C, Rey A, Morice P, Roche B, Lhommé C, Haie-Meder C and Duvillard P: Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88: 1425-1431, 2000.
4. Mayerhofer K, Obermair A, Windbichler G, Petru E, Kaider A, Hefler L, Czerwenka K, Leodolter S and Kainz C: Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 74: 196-201, 1999.
5. Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK and Lewis JL Jr: Treatment of uterine leiomyosarcoma. Obstet Gynecol 71: 845-850, 1988.
6. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, Yordan E and Brady MF: Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71: 1702-1709, 1993.
7. Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO and Tropé CG: The prognostic significance of stage, tumor size, cellular atypia, and DNA ploidy in uterine leiomyosarcoma. Acta Oncol 34: 797-802, 1995.
8. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, Lissoni A, Losa G and Fanucchi A: Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 63: 247-253, 1996. (Pubitemid 26398607)
9. Dinh TA, Oliva EA, Fuller AF Jr, Lee H and Goodman A: The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 92: 648-652, 2004.
10. Dinh TV and Woodruff JD: Leiomyosarcoma of the uterus. Am J Obstet Gynecol 144: 817-823, 1982.
11. Jeffers M, Rong S and Vande Woude GF: Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16: 1115-1125, 1996. (Pubitemid 26061683)
12. Comoglio PM: Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. EXS 65: 131-165, 1993.
13. Rosen EM, Nigam SK and Goldberg ID: Scatter factor and the c-Met receptor: a paradigm for mesenchymal/epithelial interactions. J Cell Biol 127: 1783-1787, 1994.
14. Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M and Vande Woude GF: Met expression and sarcoma tumorigenicity. Cancer Res 53: 5355-5360, 1993.
15. Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K and Kitamura N: Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 272: 6370-6376, 1997.
16. Kawaguchi T, Qin L, Shimomura T, Kondo J, Matsumoto K, Denda K and Kitamura N: Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem 272: 27558-27564, 1997. (Pubitemid 27473546)
17. Kataoka H, Itoh H, Nuki Y, Hamasuna R, Naganuma S, Kitamura N and Shimomura T: Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator. Biochem Biophys Res Commun 290: 1096-1100, 2002.
18. Müller-Pillasch F, Wallrapp C, Bartels K, Varga G, Friess H, Büchler M, Adler G and Gress TM: Cloning of a new Kunitztype protease inhibitor with a putative transmembrance domain overexpressed in pancreatic cancer. Biochim Biophys Acta 1395: 88-95, 1998. (Pubitemid 28035524)
19. Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B and Moran P: Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett 579: 1945-1950, 2005.
20. Kataoka H, Miyata S, Uchinokura S and Itoh H: Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 22: 223-236, 2003.
21. Fan B, Wu TD, Li W and Kirchhofer D: Identification of hepatocyte growth factor activator inhibitor-1B as a potential physiological inhibitor of prostasin. J Biol Chem 280: 34513-34520, 2005.
22. Kataoka H, Hamasuna R, Itoh H, Kitamura N and Koono M: Activation by hepatocyte growth factor/scatter in colorectal carcinoma. Cancer Res 60: 6148-6159, 2000.
23. Delaria KA, Muller DK, Marlor CW, Brown JE, Das RC, Roczniak SO and Tamburini PP: Characterization of placental bikunin, a novel human serine protease inhibitor. J Biol Chem 272: 12209-12214, 1997. (Pubitemid 27202806)
24. Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H and Hiramatsu Y: Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer. Ann Oncol 20: 63-70, 2009.
25. Nakamura K, Abarzua F, Kodama J, Hongo A, Nasu Y, Kumon H and Hiramatsu Y: Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer. Int J Oncol 34: 345-353, 2009.
26. Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H and Hiramatsu Y: The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer. Int J Oncol 35: 239-248, 2009.
27. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF and Mukhtar H: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15: 217-227, 2006.
28. Parr C, Watkins G, Mansel RE and Jiang WG: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10: 202-211, 2004. (Pubitemid 38114181)
29. Zeng L, Cao J and Zhang X: Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 11: 6202-6207, 2005.
30. Hamasuna R, Kataoka H, Meng JY, Itoh H, Moriyama T, Wakisaka S and Koono M: Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells. Int J Cancer 93: 339-345, 2001. (Pubitemid 32592051)
31. Fukai K, Yokosuka O, Chiba T, Hirasawa Y, Tada M, Imazeki F, Kataoka H and Saisho H: Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma. Cancer Res 63: 8674-8679, 2003.
32. Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y and Kataoka H: Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 98: 491-498, 2007. (Pubitemid 46562738)
33. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, Miyazawa K and Koono M: Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 275: 40453-40462, 2000.
34. Nakamura K, Nasu Y, Hongo A, Matsuo T, Kodama J, Ebara S, Nagai A, Abrzua F, Kumon H and Hiramatsu Y: Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines. Int J Oncol 28: 393-398, 2006.
35. Cheng H, Fukushima T, Takahashi N, Tanaka H and Kataoka H: Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res 69: 1828-1835, 2009.
36. Sakashita K, Mimori K, Tanaka F, Tahara K, Inoue H, Sawada T, Ohira M, Hirakawa K and Mori M: Clinical significance of low expression of Prostasin mRNA in human gastric cancer. J Surg Oncol 98: 559-564, 2008.
37. Nagakawa O, Yamagishi T, Fujiuchi Y, Junicho A, Akashi T, Nagaike K and Fuse H: Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. Eur Urol 48: 686-690, 2005. (Pubitemid 41278597)
38. Szabo R, Hobson JP, List K, Molinolo A, Lin CY and Bugge TH: Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity. J Biol Chem 283: 29495-29504, 2008.
39. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH and Antalis TM: Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev 22: 237-258, 2003.
40. Lee SL, Dickson RB and Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275: 36720-36725, 2000.
41. Moran P, Li W, Fan B, Vij R, Eigenbrot C and Kirchhofer D: Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 281: 30439-30446, 2006. (Pubitemid 44596152)
42. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR and Crai CS: Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275: 26333-26342, 2000.
43. Netzel-Arnett S, Currie BM, Szabo R, Lin CY, Chen LM, Chai KX, Antalis TM, Bugge TH and List K: Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem 281: 32941-32945, 2006.
44. Parr C and Jiang WG: Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer 119: 1176-1183, 2006.
45. Sanders AJ, Parr C, Mason MD and Jiang WG: Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med 20: 613-619, 2007.
46. Miyata S, Fukushima T, Kohama K, Tanaka H, Takeshima H and Kataoka H: Roles of Kunitz domains in the anti-invasive effect of hepatocyte growth factor activator inhibitor type 1 in human glioblastoma cells. Hum Cell 20: 100-106, 2007. (Pubitemid 47621823)